This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I often catch myself thinking about the power of social conditioning and the myth of normal that society imposes on us all. The myth of normal tells us that we should follow a certain path and hit a certain milestone by a specific age: school, career, family, retirement, etc. I know first-hand the pressure of cultural norms, the myth of norms. Accordingly, I was supposed to have a career breakthrough during my 20s, find the perfect partner by my early 30s, settle down with kids of my own, and ha
Hyman, Phelps & McNamara (“HPM”) Director Larry Houck will present “Prescribing Red Flags, Corresponding Responsibility and DEA Investigations: What’s a Pharmacist To Do?” at this year’s American Pharmacists Association’s (“APhA’s”) Annual Meeting in Phoenix, March 24-27. Mr. Houck was a diversion investigator with the Drug Enforcement Administration (“DEA”) in the field and at agency headquarters for 15 years before joining HPM in 2001.
Congestion causes | Common decongestants | Best decongestants for ears | Side effects | Other treatment options | When to see a doctor If you’re experiencing ear congestion while sick with the common cold or the flu, you might be looking for the best decongestant for the ears. The best decongestant will depend on the underlying cause and the type of symptoms present.
The kidney plays many vital roles in the body. One of those roles is to eliminate medications and their metabolites. When the kidney is not functioning well, drugs are eliminated from the body at a slower rate and can accumulate. Those higher drug concentrations can lead to an increased risk for toxicity. In this post, […] The post Top 10 Drugs Affected By Renal Function appeared first on Med Ed 101.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Read a compelling, detailed Case Study about how an innovation partnership with Waters Corporation enhanced Alcami’s capacity, efficiency, and compliance-readiness for their pharmaceutical manufacturing and analytical services to differentiate their offerings and drive business growth.
Shots: Through this agreement, clover received commercial rights for the distribution of AdimFlu-S in mainland China. The NMPA approved it in Jan 2022 for individuals aged ≥3yrs.
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Camrelizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Camrelizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Watching news reports of the heroic relief efforts underway in Turkey and Syria following the devastating earthquake there, I can imagine the terrible weight of emotional trauma that so many people are experiencing right now because I’ve experienced it myself. A dozen years ago, as a young doctor with a background in emergency medicine, I felt prepared to handle disaster response situations.
AT-1412 is under clinical development by Kling Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-1412’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
What is an inner ear infection? | Symptoms | Causes | Treatment | When to see a doctor Chances are, you or someone you know has experienced an ear infection. But did you know that there are several different types of ear infections? The most common ear infection —especially in children—is known as otitis media or acute otitis media, which means a middle ear infection.
Annexuzlimab is under clinical development by MedAnnex and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase I drugs for Kidney Cancer (Renal Cell Cancer) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Annexuzlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
UK hospital admissions for COPD and asthma have significantly increased over the last 21 years despite an increase in prescribed treatments In an analysis of hospital admissions for both chronic obstructive pulmonary disease (COPD) and asthma from 1999 to 2020, it was found that there was a significant increase for both conditions despite a considerable increase in prescribed treatments for these diseases.
LYT-200 is under clinical development by Puretech Health and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LYT-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Shots: Pfizer has discontinued the evaluation of 50% of the patients with Lyme disease enrolled in the P-III clinical trial (VALOR) that analyses the safety, efficacy & immunogenicity of VLA15 The discontinuation was marked following the violations of GCP at certain clinical trial sites run by a third-party trial site operator. The clinical trials remain ongoing as Pfizer continues to enroll new patients at those sites VLA15 is a Lyme disease vaccine candidate that blocks the outer surface p
STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STRO-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Danburstotug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Zelenoleucel is under clinical development by Marker Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zelenoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
98 
Let's personalize your content